Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Marc A. Pfeffer; Brian Claggett; Eldrin F. Lewis; Christopher B. Granger; Lars Køber; Aldo P. Maggioni; Douglas L. Mann; John J.V. McMurray; Jean-Lucien Rouleau; Scott D. Solomon; Philippe Gabriel Steg; Otavio Berwanger; Maja Cikes; Carmine G. De Pasquale; Alberto Fernandez; Gerasimos Filippatos; Karola Jering; Ulf Landmesser; Venugopal Menon; Béla Merkely; Mark C. Petrie; Ivo Petrov; Morten Schou; Michele Senni; David Sim; Peter Van Der Meer; Martin Lefkowitz; Yinong Zhou; Yi Wang; Eugene Braunwald

doi:10.1161/CIRCULATIONAHA.121.057429

Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Marc A. Pfeffer, Brian Claggett, Eldrin F. Lewis, Christopher B. Granger, Lars Køber, Aldo P. Maggioni, Douglas L. Mann, John J.V. McMurray, Jean-Lucien Rouleau, Scott D. Solomon, Philippe Gabriel Steg, Otavio Berwanger, Maja Cikes, Carmine G. De Pasquale, Alberto Fernandez, Gerasimos Filippatos, Karola Jering, Ulf Landmesser, Venugopal Menon, Béla MerkelyMark C. Petrie, Ivo Petrov, Morten Schou, Michele Senni, David Sim, Peter Van Der Meer, Martin Lefkowitz, Yinong Zhou, Yi Wang, Eugene Braunwald

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

45 Citations (Scopus)

Abstract

The hypothesis that sacubitril/valsartan is superior to ramipril in reducing time-to-first cardiovascular death or the development of heart failure (hospitalization or outpatient) in patients with acute myocardial infarction was tested in PARADISE-MI (Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after MI).1 The risk of this primary composite outcome using the prespecified time-to-first event analysis of the clinical end point committee (CEC)–adjudicated events was not significantly reduced in the sacubitril/valsartan group.2 As such, all secondary analyses are considered exploratory.

Original language	English
Pages (from-to)	87-89
Number of pages	3
Journal	Circulation
Volume	145
Issue number	1
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.121.057429
Publication status	Published - 4 Jan 2022

Keywords

heart failure
myocardial infarction
ramipril
sacubitril/valsartan

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.121.057429Licence: In Copyright

Cite this

Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J.-L., Solomon, S. D., Steg, P. G., Berwanger, O., Cikes, M., De Pasquale, C. G., Fernandez, A., Filippatos, G., Jering, K., Landmesser, U., Menon, V., ... Braunwald, E. (2022). Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 145(1), 87-89. https://doi.org/10.1161/CIRCULATIONAHA.121.057429

@article{f579f83b2c594d2ca9eb73acc007c63b,

title = "Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial",

abstract = "The hypothesis that sacubitril/valsartan is superior to ramipril in reducing time-to-first cardiovascular death or the development of heart failure (hospitalization or outpatient) in patients with acute myocardial infarction was tested in PARADISE-MI (Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after MI).1 The risk of this primary composite outcome using the prespecified time-to-first event analysis of the clinical end point committee (CEC)–adjudicated events was not significantly reduced in the sacubitril/valsartan group.2 As such, all secondary analyses are considered exploratory.",

keywords = "heart failure, myocardial infarction, ramipril, sacubitril/valsartan",

author = "Pfeffer, {Marc A.} and Brian Claggett and Lewis, {Eldrin F.} and Granger, {Christopher B.} and Lars K{\o}ber and Maggioni, {Aldo P.} and Mann, {Douglas L.} and McMurray, {John J.V.} and Jean-Lucien Rouleau and Solomon, {Scott D.} and Steg, {Philippe Gabriel} and Otavio Berwanger and Maja Cikes and {De Pasquale}, {Carmine G.} and Alberto Fernandez and Gerasimos Filippatos and Karola Jering and Ulf Landmesser and Venugopal Menon and B{\'e}la Merkely and Petrie, {Mark C.} and Ivo Petrov and Morten Schou and Michele Senni and David Sim and {Van Der Meer}, Peter and Martin Lefkowitz and Yinong Zhou and Yi Wang and Eugene Braunwald",

year = "2022",

month = jan,

day = "4",

doi = "10.1161/CIRCULATIONAHA.121.057429",

language = "English",

volume = "145",

pages = "87--89",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

Pfeffer, MA, Claggett, B, Lewis, EF, Granger, CB, Køber, L, Maggioni, AP, Mann, DL, McMurray, JJV, Rouleau, J-L, Solomon, SD, Steg, PG, Berwanger, O, Cikes, M, De Pasquale, CG, Fernandez, A, Filippatos, G, Jering, K, Landmesser, U, Menon, V, Merkely, B, Petrie, MC, Petrov, I, Schou, M, Senni, M, Sim, D, Van Der Meer, P, Lefkowitz, M, Zhou, Y, Wang, Y & Braunwald, E 2022, 'Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial', Circulation, vol. 145, no. 1, pp. 87-89. https://doi.org/10.1161/CIRCULATIONAHA.121.057429

TY - JOUR

T1 - Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

AU - Pfeffer, Marc A.

AU - Claggett, Brian

AU - Lewis, Eldrin F.

AU - Granger, Christopher B.

AU - Køber, Lars

AU - Maggioni, Aldo P.

AU - Mann, Douglas L.

AU - McMurray, John J.V.

AU - Rouleau, Jean-Lucien

AU - Solomon, Scott D.

AU - Steg, Philippe Gabriel

AU - Berwanger, Otavio

AU - Cikes, Maja

AU - De Pasquale, Carmine G.

AU - Fernandez, Alberto

AU - Filippatos, Gerasimos

AU - Jering, Karola

AU - Landmesser, Ulf

AU - Menon, Venugopal

AU - Merkely, Béla

AU - Petrie, Mark C.

AU - Petrov, Ivo

AU - Schou, Morten

AU - Senni, Michele

AU - Sim, David

AU - Van Der Meer, Peter

AU - Lefkowitz, Martin

AU - Zhou, Yinong

AU - Wang, Yi

AU - Braunwald, Eugene

PY - 2022/1/4

Y1 - 2022/1/4

N2 - The hypothesis that sacubitril/valsartan is superior to ramipril in reducing time-to-first cardiovascular death or the development of heart failure (hospitalization or outpatient) in patients with acute myocardial infarction was tested in PARADISE-MI (Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after MI).1 The risk of this primary composite outcome using the prespecified time-to-first event analysis of the clinical end point committee (CEC)–adjudicated events was not significantly reduced in the sacubitril/valsartan group.2 As such, all secondary analyses are considered exploratory.

AB - The hypothesis that sacubitril/valsartan is superior to ramipril in reducing time-to-first cardiovascular death or the development of heart failure (hospitalization or outpatient) in patients with acute myocardial infarction was tested in PARADISE-MI (Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after MI).1 The risk of this primary composite outcome using the prespecified time-to-first event analysis of the clinical end point committee (CEC)–adjudicated events was not significantly reduced in the sacubitril/valsartan group.2 As such, all secondary analyses are considered exploratory.

KW - heart failure

KW - myocardial infarction

KW - ramipril

KW - sacubitril/valsartan

UR - http://www.scopus.com/inward/record.url?scp=85123225487&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.121.057429

DO - 10.1161/CIRCULATIONAHA.121.057429

M3 - Article

C2 - 34797725

AN - SCOPUS:85123225487

SN - 0009-7322

VL - 145

SP - 87

EP - 89

JO - Circulation

JF - Circulation

IS - 1

ER -

Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this